Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.88
+0.61 (7.38%)
At close: Nov 20, 2024, 4:00 PM
9.00
+0.12 (1.35%)
Pre-market: Nov 21, 2024, 7:39 AM EST
Emergent BioSolutions Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,126 | 1,049 | 1,118 | 1,774 | 1,577 | 1,106 | Upgrade
|
| Revenue Growth (YoY) | 2.05% | -6.10% | -36.99% | 12.45% | 42.61% | 41.36% | Upgrade
|
| Cost of Revenue | 835.2 | 807.1 | 827.4 | 980.4 | 714.2 | 622.9 | Upgrade
|
| Gross Profit | 290.3 | 242.2 | 290.1 | 793.2 | 863.1 | 483.1 | Upgrade
|
| Selling, General & Admin | 339.1 | 368.4 | 339.5 | 348.7 | 304.1 | 273.5 | Upgrade
|
| Operating Expenses | 404.1 | 434 | 399.4 | 407.2 | 363.9 | 332.2 | Upgrade
|
| Operating Income | -113.8 | -191.8 | -109.3 | 386 | 499.2 | 150.9 | Upgrade
|
| Interest Expense | -77.9 | -87.9 | -37.3 | -34.5 | -31.3 | -38.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 26.8 | 8.9 | -11.7 | -3.7 | 4.7 | 1.7 | Upgrade
|
| EBT Excluding Unusual Items | -164.9 | -270.8 | -158.3 | 347.8 | 472.6 | 114.2 | Upgrade
|
| Merger & Restructuring Charges | -29 | -9.5 | -51.4 | - | - | - | Upgrade
|
| Impairment of Goodwill | - | -218.2 | -6.7 | -41.7 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 24.3 | 74.2 | - | - | - | - | Upgrade
|
| Asset Writedown | - | -306.7 | - | - | -29 | -12 | Upgrade
|
| Other Unusual Items | -0.2 | -0.2 | -2.6 | -2.9 | -31.7 | -24.8 | Upgrade
|
| Pretax Income | -169.8 | -731.2 | -219 | 303.2 | 411.9 | 77.4 | Upgrade
|
| Income Tax Expense | 39 | 29.3 | -7.4 | 83.7 | 106.1 | 22.9 | Upgrade
|
| Earnings From Continuing Operations | -208.8 | -760.5 | -211.6 | 219.5 | 305.8 | 54.5 | Upgrade
|
| Net Income to Company | -208.8 | -760.5 | -211.6 | 219.5 | 305.8 | 54.5 | Upgrade
|
| Net Income | -208.8 | -760.5 | -211.6 | 219.5 | 305.8 | 54.5 | Upgrade
|
| Net Income to Common | -208.8 | -760.5 | -211.6 | 219.5 | 305.8 | 54.5 | Upgrade
|
| Net Income Growth | - | - | - | -28.22% | 461.10% | -13.08% | Upgrade
|
| Shares Outstanding (Basic) | 52 | 51 | 50 | 54 | 53 | 52 | Upgrade
|
| Shares Outstanding (Diluted) | 52 | 51 | 50 | 54 | 54 | 52 | Upgrade
|
| Shares Change (YoY) | 3.65% | 2.20% | -7.39% | 0.56% | 2.67% | 1.95% | Upgrade
|
| EPS (Basic) | -3.98 | -14.85 | -4.22 | 4.10 | 5.80 | 1.06 | Upgrade
|
| EPS (Diluted) | -3.98 | -14.85 | -4.22 | 4.06 | 5.68 | 1.04 | Upgrade
|
| EPS Growth | - | - | - | -28.52% | 446.15% | -14.75% | Upgrade
|
| Free Cash Flow | 138.1 | -257.9 | -149.9 | 96.1 | 395 | 101.1 | Upgrade
|
| Free Cash Flow Per Share | 2.63 | -5.04 | -2.99 | 1.78 | 7.34 | 1.93 | Upgrade
|
| Gross Margin | 25.79% | 23.08% | 25.96% | 44.72% | 54.72% | 43.68% | Upgrade
|
| Operating Margin | -10.11% | -18.28% | -9.78% | 21.76% | 31.65% | 13.64% | Upgrade
|
| Profit Margin | -18.55% | -72.48% | -18.94% | 12.38% | 19.39% | 4.93% | Upgrade
|
| Free Cash Flow Margin | 12.27% | -24.58% | -13.41% | 5.42% | 25.04% | 9.14% | Upgrade
|
| EBITDA | -4.8 | -70.7 | 15.7 | 504.2 | 609.2 | 258.9 | Upgrade
|
| EBITDA Margin | -0.43% | -6.74% | 1.40% | 28.43% | 38.62% | 23.41% | Upgrade
|
| D&A For EBITDA | 109 | 121.1 | 125 | 118.2 | 110 | 108 | Upgrade
|
| EBIT | -113.8 | -191.8 | -109.3 | 386 | 499.2 | 150.9 | Upgrade
|
| EBIT Margin | -10.11% | -18.28% | -9.78% | 21.76% | 31.65% | 13.64% | Upgrade
|
| Effective Tax Rate | - | - | - | 27.61% | 25.76% | 29.59% | Upgrade
|
| Revenue as Reported | 1,157 | 1,049 | 1,118 | 1,774 | 1,577 | 1,106 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.